Your registration includes access to the recording on demand through December 31, 2023.
DESCRIPTION
Understanding the requirements for revalidation of molecular microbiology testing instrumentation can be challenging for laboratory leaders. Regulatory agencies such as CAP and CLIA often require revalidation but provide minimal guidance on what additional testing is required prior to putting instruments back into clinical use. Further, practical and actionable guidance on when and how to revalidate testing instruments is largely unavailable.
This webinar will provide an overview of the CAP/CLIA check list items relevant to revalidation of molecular microbiology testing instruments. It will also address when and how revalidations of instruments should be performed. Finally, using a case-based approach, it will discuss general best practices associated with revalidation of laboratory instruments, including to what extent (e.g., sample types, sample size, etc.) testing is needed for commonly encountered scenarios.
TARGET AUDIENCE
This activity is designed for lab supervisors, lab managers (supervisory and/or non-supervisory), medical technologists, residents, and other laboratory professionals overseeing/conducting within this topic.
LEARNING OBJECTIVES
At the end of this activity, participants will be able to:
- Summarize the relevant CAP and CLIA check list items requiring revalidation of testing instruments
- Describe common laboratory scenarios requiring revalidation of testing instruments
- Discuss best practices for the extent of revalidation required by regulatory agencies
FACULTY
Rachael Liesman, PhD, D(ABMM)
Director, Clinical Microbiology
Director, Molecular Microbiology
Clinical Associate Professor
Department of Pathology and Laboratory Medicine
University of Kansas Health System
Kansas City, KS
DISCLOSURES AND STATEMENT OF INDEPENDENCE
AACC is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.
The following faculty reported the following relevant financial relationship(s) during the content development process for this activity:
- Rachael Liesman, PhD, D(ABMM)
Grant/Research Support: Abbott
Presenter/Speaker: Roche
CONTENT VALIDITY
All recommendations involving clinical medicine are based on evidence accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients; AND/OR all scientific research referred to or reported in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis.
ACCREDITATION STATEMENT
This activity is approved for 1.0 ACCENT® continuing education credits. Activity ID# 4145. This activity was planned in accordance with ACCENT® Standards and Policies.
SUCCESSFUL COMPLETION STATEMENT
Verification of Participation certificates are provided to registered participants based on completion of the activity, in its entirety, and the activity evaluation. For questions regarding continuing education, please email [email protected].